Clinical Trial Update: A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating radiation therapy combined with pembrolizumab and olaparib (or other radiosensitizers) in women with triple-negative or h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone Receptor-positive Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Olaparib (Olaparib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 2 | Status: RECRUITING